Friday, August 15, 2025 8/15/2025

Using DNA Methylation Markers for Diagnosis and Prognosis of Upper Tract Urothelial Carcinoma

Award Number: R21CA288920
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2026

Group Awards By:

View Award Description

Using DNA Methylation Markers for Diagnosis and Prognosis of Upper Tract Urothelial Carcinoma - SUMMARY Upper Tract Urothelial Carcinoma (UTUC) is a rare disease that accounts for 5-10% of all urothelial tumors with an estimated annual incidence in Western countries of almost two cases per 100,000 inhabitants. The 5- year specific survival is < 50% for stage 2-3 patients but < 10% for those with stage 4 disease. This poor survival rate demands improvements in preoperative detection. Diagnosis and preoperative risk-stratification of UTUC patients present distinct challenges given the limitations of current available tools. Although urine cytology has an acceptable specificity to detect UTUC, the sensitivity is relatively low, particularly in low-grade carcinomas and pelvicalyceal tumors. The invasive ureteroscopy (URS) biopsy can enhance the diagnostic accuracy, yet under-grading and under-staging rates remain a concern at 32% and 46%, respectively. Nowadays, clinical decision-making and the prognosis of UTUC relies heavily on TNM stage and pathological grade that is not accurately available until radical nephroureterectomy (RNU) is performed. Major improvements in predictive tools have occurred in recent years and unique parameters have been proposed to distinguish between low- and high- risk tumors. DNA methylation alterations have emerged as potential diagnostic and prognostic factors for urothelial carcinoma at the molecular level. For example, bladder cancer-specific DNA methylation changes can be detected in urine sediments and can be used as non-invasive diagnostic or surveillance markers. Thus, a personalized medicine approach for the diagnosis and prognosis of UTUC is urgently needed. The goal of this study is to develop DNA methylation biomarkers to identify aggressiveness of UTUC. In a preliminary study, we identified differential DNA methylation patterns in a small group of patients who had exhibited DNA markers for UTUC aggressiveness. We hypothesize that bladder cancer DNA methylation marker panels can be used to: 1) characterize UTUC-specific and/or aggressive UTUC specific DNA methylation markers in primary UTUC specimens (Aim 1); 2) validate these markers in urine sediments of UTUC patients for monitoring disease diagnosis, prognosis and recurrence (Aim 2). Results from this proposal will support further independent investigations into the role of DNA methylation markers in UTUC diagnosis and prognosis, improve the standard of care in predictive tools and different parameters have been proposed to distinguish between low- and high- risk tumors and provide UTUC-specific DNA methylation profiles that aid physicians’ decisions.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $194,013 )
2025	2025	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	2	2/28/2025	NON-COMPETING CONTINUATION	$174,612
2025	2025	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90033	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	001	2	5/23/2025	NON-COMPETING CONTINUATION	$19,401
														Subtotal = $194,013

Issue Date FY: 2024 ( Subtotal = $232,640 )
2024	2024	UNIVERSITY OF SOUTHERN CALIFORNIA	3720 S FLOWER ST FL 3	LOS ANGELES	CA	90089	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	1	2/27/2024	NEW	$232,640
														Subtotal = $232,640

Grand Total All Awards = $426,653

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Using DNA Methylation Markers for Diagnosis and Prognosis of Upper Tract Urothelial Carcinoma

Award Number: R21CA288920

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer